Leigh Brody
Direktor/Vorstandsmitglied bei Bloomsbury Genetic Therapies Ltd.
Profil
Leigh Brody is currently the Director at Bloomsbury Genetic Therapies Ltd.
and Investment Manager at Albion Capital Group LLP.
Brody holds a doctorate degree from Imperial College London and an undergraduate degree from Simmons University.
Aktive Positionen von Leigh Brody
| Unternehmen | Position | Beginn |
|---|---|---|
Albion Capital Group LLP
 Albion Capital Group LLP Investment ManagersFinance Albion Ventures LLP (Albion Ventures) is a venture capital firm founded in 1996. The firm is headquartered in London. | Private Equity Investor | 01.01.2021 |
Bloomsbury Genetic Therapies Ltd.
 Bloomsbury Genetic Therapies Ltd. BiotechnologyHealth Technology Bloomsbury Genetic Therapies Ltd. is a British biotechnology company that specializes in developing gene therapy technologies for neurological and metabolic diseases. The company is based in Cambridge, UK. Bloomsbury Genetic Therapies was founded in 2021 by Adrien Lemoine, who has been the CEO since 2021. | Direktor/Vorstandsmitglied | 01.04.2022 |
Ausbildung von Leigh Brody
| Simmons University | Undergraduate Degree |
| Imperial College London | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Albion Capital Group LLP
Albion Capital Group LLP Investment ManagersFinance Albion Ventures LLP (Albion Ventures) is a venture capital firm founded in 1996. The firm is headquartered in London. | Finance |
Bloomsbury Genetic Therapies Ltd.
Bloomsbury Genetic Therapies Ltd. BiotechnologyHealth Technology Bloomsbury Genetic Therapies Ltd. is a British biotechnology company that specializes in developing gene therapy technologies for neurological and metabolic diseases. The company is based in Cambridge, UK. Bloomsbury Genetic Therapies was founded in 2021 by Adrien Lemoine, who has been the CEO since 2021. | Health Technology |